BCRX  Biocryst Pharmaceuticals Inc.

Exchange

NASDAQ

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.

784.0M

Vuru Grade

21.00/100

Current Price

$10.91
0.00 (0.00%)

Stability Price

$0.19
Overvalued by 98.29%

Company Metrics

  • 0 P/E
  • 41.86 P/S
  • 9.4 P/B
  • -0.613 EPS
  • -118.77% Cash ROIC
  • 2.49 Cash Ratio
  • 0 / 0% Dividend
  • 1.23M Avg. Vol.
  • 55.22M Shares
  • 784.0M Market Cap.

Company Description

BioCryst Pharmaceuticals, Inc. designs, optimizes, and develops small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer, and inflammatory diseases. It uses structure-based drug design, which incorporates multiple scientific disciplines, including biology, crystallography, medicinal chemistry, and computer modeling to develop new therapeutic candidates. The com...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Stock Update: BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX)
Markets Wired - Dec 12, 2014
[GLOBE NEWSWIRE] BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) (TREND ANALYSIS) announced financial results for the third quarter ended September 30, 2014.
BioCryst Pharmaceuticals Inc. (BCRX) Has Broken Out Of Today's Range
NASDAQ - Oct 14, 2014
BioCryst Pharmaceuticals Inc. (BCRX) Has Broken Out Of Today's Range. By RTT News, October 14, 2014, 10:12:00 AM EDT. A A A. Vote up.
BioCryst Pharmaceuticals's "Buy" Rating Reiterated at Noble Financial (BCRX)
sleekmoney - Dec 17, 2014
BioCryst Pharmaceuticals, Inc. logo Noble Financial reissued their buy rating on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) in a research report sent to investors on Monday morning.
BioCryst Pharmaceuticals's Buy Rating Reiterated at Noble Financial (BCRX) - Intercooler
Stock Update: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
Markets Wired - Dec 3, 2014
[GLOBE NEWSWIRE] BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced financial results for the third quarter ended September 30, 2014.
Dyax Corp. (DYAX), BioCryst Pharmaceuticals, Inc. (BCRX), Achillion ... - StockWise Daily
BioCryst Pharmaceuticals Trading Down 4.7% After Analyst Downgrade (BCRX) - WKRB News
Why BioCryst Pharmaceuticals Inc. Shares Soared
Motley Fool - May 27, 2014
What: Shares of BioCryst Pharmaceuticals (NASDAQ: BCRX ) , a biotechnology company focused on developing small-molecule drugs designed to block enzymes which are vital to the disease development process, spiked higher by as much as 22% after ...
BioCryst Crushes It on Rare Immune Disorder Drug Trial - 24/7 Wall St.
BioCryst Announces Positive Results From OPuS-1, a Phase 2 Trial of BCX4161 ... - MarketWatch
Stock Update: BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) to Present at ...
Markets Wired - Nov 25, 2014
Taking a look at the company's recent performance, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) reported Third quarter earnings for fiscal 2014 on November 06th.
High Short Interest Alert:Biocryst Pharmaceuticals , Avanir Pharmaceuticals Inc - Markets Insider
Worth Watching Stocks - BioCryst Pharmaceuticals, Inc.(NASDAQ:BCRX ... - Techsonian (press release)
Can BioCryst Pharmaceuticals, Inc. (BCRX) Stop The Ebola Outbreak?
ETF Daily News - Aug 5, 2014
Currently there are no approved vaccines or drugs to treat Ebola. All doctors can do is give patients fluid and try to stop the bleeding that Ebola causes.
Biocryst Pharmaceuticals (BCRX) Highlighted As Today's Perilous Reversal Stock - TheStreet.com
BioCryst Pharmaceuticals' (BCRX) CEO Jon Stonehouse on Q2 2014 Results ... - Seeking Alpha (registration)
BioCryst Pharmaceuticals (BCRX) Reports Ahead Of Street For Q3
Bidness ETC - Nov 6, 2014
Today, drug maker BioCryst Pharmaceuticals, Inc. (BCRX) posted quarterly results for the three-month period ended September 30.
BioCryst Reports Third Quarter 2014 Financial Results - GlobeNewswire (press release)
BioCryst Pharma Inc (BCRX) Coverage Initiated By JP Morgan With Overweight
Wall Street Pit - Aug 8, 2014
BioCryst Pharmaceuticals, Inc. (BCRX) was initiated with a 'Overweight' and it was given a $20.00 price target at JP Morgan (JPM) in a research report issued to clients on Friday.
UPDATE: JPMorgan Starts BioCryst Pharma (BCRX) at Overweight - StreetInsider.com (subscription)
BioCryst to Launch NHP Ebola Drug Safety, Efficacy Studies 'Within Weeks'
Forbes - Aug 29, 2014
BioCryst Pharmaceuticals, Inc. announced this morning that their small-molecule, nucleoside analogue, BCX-4430, would be entering a dose ranging efficacy study in non-human primates within the next few weeks.
Hope For Ebola Cure - Bidness ETC
BioCryst expects to begin Ebola study in weeks - Yahoo News